Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $65.6 million.

  • Aytu Biopharma's Total Current Liabilities rose 236.54% to $65.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $65.6 million, marking a year-over-year increase of 236.54%. This contributed to the annual value of $63.1 million for FY2025, which is 134.34% up from last year.
  • Aytu Biopharma's Total Current Liabilities amounted to $65.6 million in Q4 2025, which was up 236.54% from $66.0 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Total Current Liabilities ranged from a high of $109.4 million in Q2 2021 and a low of $61.3 million during Q3 2024
  • For the 5-year period, Aytu Biopharma's Total Current Liabilities averaged around $74.9 million, with its median value being $68.1 million (2022).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 35567.48% in 2021, then plummeted by 4111.55% in 2022.
  • Aytu Biopharma's Total Current Liabilities (Quarter) stood at $100.6 million in 2021, then tumbled by 33.23% to $67.1 million in 2022, then fell by 4.41% to $64.2 million in 2023, then decreased by 0.22% to $64.0 million in 2024, then increased by 2.37% to $65.6 million in 2025.
  • Its last three reported values are $65.6 million in Q4 2025, $66.0 million for Q3 2025, and $63.1 million during Q2 2025.